Literature DB >> 11550123

Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999).

J S Yang1, J J Kim, D Hwang, A Y Choo, K Dang, H Maguire, S Kudchodkar, M P Ramanathan, D B Weiner.   

Abstract

West Nile virus (WNV) is a vectorborne pathogen that induces brain inflammation and death. Recently, confirmed cases of infection and deaths have occurred in the United States Mid-Atlantic region. In this study, a DNA vaccine encoding the WNV capsid protein was constructed, and the in vivo immune responses generated were investigated in DNA vaccine-immunized mice. Antigen-specific humoral and cellular immune responses were observed, including a potent induction of antigen-specific Th1 and cytotoxic T lymphocyte responses. Strong induction of Th1-type immune responses included high levels of antigen-specific elaboration of the Th1-type cytokines interferon-gamma and interleukin-2 and beta-chemokines RANTES (regulated upon activation, normal T cell-expressed and secreted) and macrophage inflammatory protein-1beta. Dramatic infiltration of CD4 and CD8 T cells and macrophages also was observed at the muscle injection site. These results support the potential utility of this method as a tool for developing immunization strategies for WNV and other emerging pathogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11550123     DOI: 10.1086/323395

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  Structure and function of the 3' terminal six nucleotides of the west nile virus genome in viral replication.

Authors:  Mark Tilgner; Pei-Yong Shi
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 2.  West Nile virus: a growing concern?

Authors:  L Hannah Gould; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 3.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

Authors:  Dominick J Laddy; Jian Yan; Natasha Corbitt; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2007-01-30       Impact factor: 3.641

Review 5.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

6.  Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.

Authors:  Lauren A Hirao; Ling Wu; Amir S Khan; David A Hokey; Jian Yan; Anlan Dai; Michael R Betts; Ruxandra Draghia-Akli; David B Weiner
Journal:  Vaccine       Date:  2008-03-11       Impact factor: 3.641

7.  West nile virus: current perspectives.

Authors:  Om Prakash; George Pankey
Journal:  Ochsner J       Date:  2003

8.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

9.  Evaluation of a DNA vaccine candidate co-expressing GP3 and GP5 of porcine reproductive and respiratory syndrome virus (PRRSV) with interferon α/γ in immediate and long-lasting protection against HP-PRRSV challenge.

Authors:  Yijun Du; Jing Qi; Yu Lu; Jiaqiang Wu; Dongwan Yoo; Xing Liu; Xiumei Zhang; Jun Li; Wenbo Sun; Xiaoyan Cong; Jianli Shi; Jinbao Wang
Journal:  Virus Genes       Date:  2012-07-28       Impact factor: 2.332

10.  IL-10 signaling blockade controls murine West Nile virus infection.

Authors:  Fengwei Bai; Terrence Town; Feng Qian; Penghua Wang; Masahito Kamanaka; Tarah M Connolly; David Gate; Ruth R Montgomery; Richard A Flavell; Erol Fikrig
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.